Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...
Zacks.com on MSN8h
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...
GlobalData on MSN10h
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trialThe Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...
GlobalData on MSN1d
Lead Gilead researcher highlights need for inclusive clinical trials for HIVConsidering “health equity aspects”, Moupali Das highlighted the historic underrepresentation of disproportionately affected ...
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...
Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...
Gilead Sciences, the Bay Area biotech giant best known for its popular HIV drugs and COVID-19 treatment Remdesivir, is laying ...
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback